Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.44 |
| ▸ | FABP7 | O15540 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1275884 | 0.87 | CA1 (0.50) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL15436860 | 0.87 | CA1 (0.50) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL1703198 | 0.83 | CA1 (0.47) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL34473477 | 0.83 | CA1 (0.47) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL9632441 | 0.83 | TSHR (0.52) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL31370732 | 0.81 | HTR2A (0.58) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL28050 | 0.81 | HTR2A (0.58) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL4992955 | 0.81 | CA1 (0.53) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL8131 | 0.81 | CA1 (0.58) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL31501939 | 0.81 | CA1 (0.53) | CA1CA2HTR2AKMT2AFABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822146-B2 | Process for the manufacture of degarelix and its intermediates | FERRING B.V. (NL) | 2017-11-21 | — | — | US | claimed |
| US-20160145301-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | FERRING BV (NL) | 2016-05-26 | — | — | US | claimed |
| US-9822146-B2 | Process for the manufacture of degarelix and its intermediates | FERRING B.V. (NL) | 2017-11-21 | — | — | US | disclosed |
| EP-2632934-B1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | FERRING BV (NL) | 2016-11-30 | — | — | EP | disclosed |
| EP-2632935-B1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | FERRING BV (NL) | 2016-09-21 | — | — | EP | disclosed |
| US-20160145301-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | FERRING BV (NL) | 2016-05-26 | — | — | US | disclosed |
| US-9260480-B2 | Process for the manufacture of Degarelix and its intermediates | FERRING B.V. (NL) | 2016-02-16 | — | — | US | disclosed |
| US-9090656-B2 | Process for the manufacture of Degarelix and its intermediates | FERRING B.V. (NL) | 2015-07-28 | — | — | US | disclosed |
| US-20130281662-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | FERRING B.V. (NL) | 2013-10-24 | — | — | US | disclosed |
| US-20130281661-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | FERRING B.V. (NL) | 2013-10-24 | — | — | US | disclosed |
| EP-2632935-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | Ferring B.V. (NL) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012055903-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | FERRING B.V. (NL) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012055905-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | FERRING B.V. (NL) | 2012-05-03 | — | — | WO | disclosed |
| EP-2447276-A1 | Process for the manufacture of Degarelix and its intermediates | Ferring B.V. (NL) | 2012-05-02 | — | — | EP | disclosed |
| US-7045532-B2 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2002039997-A2 | ACE-2 MODULATING COMPOUNDS AND USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
| EP-1073668-A2 | SOLUTION PHASE BIOPOLYMER SYNTHESIS | Köster, Hubert (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999055718-A2 | SOLUTION PHASE BIOPOLYMER SYNTHESIS | KOESTER HUBERT (US) | 1999-11-04 | — | — | WO | disclosed |
| WO-1991008190-A1 | AMINO ACID PROTECTING GROUPS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1991-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | CA1 1746/4885CA2 699/4885HTR2A 175/4885 |
| US-20130281662-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | VIP, PM20D2, NGLY1 | CA1 237/4885CA2 1812/4885HTR2A 2580/4885 |
| US-20160145301-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | VIP, HABP2, DPP9 | CA1 327/4885CA2 1960/4885HTR2A 4091/4885 |
| US-20130281661-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | HM13, HABP2, DPP9 | CA1 321/4885CA2 2259/4885HTR2A 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.